Munich Re’s updated epidemic product gaining interest but high cost a hurdle
Munich Re is out in the market with an updated version of its Epidemic Risk Solutions (ERS) offering, with the platform seeing plenty of interest in the Covid-19 fallout although sources said take-up is not thought to be high because of the prices being quoted.
If you are a subscriber, please sign back in to read this article
If you are not currently a subscriber please see contact details below